Potential mechanisms causing delayed effects of respiratory syncytial virus infection.
Openshaw
P J
PJ
Department of Respiratory Medicine, National Heart and Lung Institute, Imperial College School of Medicine at St. Mary's, London, United Kingdom. p.openshaw@ic.ac.uk
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000627:therapeutic use; D001249:Asthma / Q000276:immunology / Q000517:prevention & control / Q000821:virology*; D001990:Bronchiolitis, Viral / Q000150:complications / Q000276:immunology* / Q000821:virology*; D004195:Disease Models, Animal; D006801:Humans; D007114:Immunization; D007223:Infant; D051379:Mice; D000069455:Palivizumab; D011657:Pulmonary Eosinophilia / Q000276:immunology / Q000821:virology; D018357:Respiratory Syncytial Virus Infections / Q000150:complications / Q000235:genetics / Q000276:immunology*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D000069455:Palivizumab